The Anti-fibrotic Effect of Human Fetal Skin-derived Stem Cell Secretome on the Liver Fibrosis

Xia Yao
First Affiliated Hospital to Changchun University of Chinese Medicine

Jing Wang
First Affiliated Hospital to Changchun University of Chinese Medicine

Jiajing Zhu
The Third Hospital of Jilin University

Xiaoli Rong (rongxl16@mails.jlu.edu.cn)
Affiliated Hospital of Changchun University of Chinese Medicine

Research

Keywords: hFSSC, secretome, liver fibrosis, TGF-β/Smad

DOI: https://doi.org/10.21203/rs.3.rs-39850/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Liver fibrosis resulting from chronic liver injury is one of the major causes of mortality worldwide. Stem cells-secreted secretome has been evaluated for overcoming the limitations of cell-based therapy in hepatic disease, while maintaining its advantages.

**Methods:** In this study, we investigated the effect of human fetal skin-derived stem cells (hFFSCs) secretome in the treatment of liver fibrosis. To determine the therapeutic potential of the hFFSCs secretome in liver fibrosis, we established the CCl$_4$-induced rat liver fibrosis model, and administered hFFSCs secretome in vivo. Moreover, we investigated the anti-fibrotic mechanism of hFFSCs secretome in hepatic stellate cells (HSCs).

**Results:** Our results showed that hFFSCs secretome effectively reduced collagen content in liver, improved the liver function and promoted liver regeneration. Interestingly, we also found that hFFSCs secretome reduced liver fibrosis through suppressing the epithelial-mesenchymal transition (EMT) process. In addition, we found that hFSSC secretom inhibited the TGF-β1, Smad2, Smad3, and Collagen I expression, however, increased Smad7 expression.

**Conclusions:** In conclusions, our results suggest that hFFSCs secretome treatment could reduce CCl$_4$-induced liver fibrosis via regulating the TGF-β/Smad signal pathway.

Introduction

Liver fibrosis is a wound healing response generated against chronic or iterative liver injury[1]. Recent evidence suggests that stem cell-based liver fibrosis treatment can be mediated through paracrine effects[2, 3]. The exclusive use of stem cell-secreted secretome, has been evaluated for overcoming the limitations of cell-based therapy, while maintaining its advantages to their parent cells[4]. It included that extracellular vesicles, and other soluble proteins or biologically active molecules. In addition, previous studies have indicated that human bone marrow mesenchymal stem cells-derived exosomes and other stem cells-derived secretome can recued liver fibrosis[5, 6].

Previous studies have indicated that the features of fetal tissue cells facilitate engraftment in vivo and may provide preferred effects against diseases difficult to treat[7]. Since 1928, hundreds of clinical trials using various types of fetal transplants have been performed worldwide[8-10]. Moreover, recently studies have been demonstrated that human fetal stem cells have a great growth promoting potential, which benefited to the tissue regeneration and cell therapy[11, 12]. In comparison to other mesenchymal stem cell (MSCs), fetal stem cells (FSCs) are easier to culture and more readily proliferate, and less likely to be rejected by transplant recipients, as these cells are less antigenic[8]. Although there remain still ethical and social issues with respect to the clinical use of fetal tissue, fetal stem cell secretome transplantation may overcome these problems and have more perspectives on hepatic disease treatment.
In our previous study, we have successfully isolated and identified hFSCs\cite{13}. Interestingly, we found hFSC secretome has great ability to control and balance the collagen formation in skin tissue\cite{13}. Therefore, we hypothesize that hFSC have a potential to reduce the collagen formation in liver fibrosis, whereas liver fibrosis is caused by over-abundance of collagen. We further analyzed the effects of hFSC secretome on liver fibrosis in vitro, and the investigated the mechanism of hFSC secretome and TGF-\(\beta\)/Smad pathway involvement on anti-fibrosis. Our preliminary results provide the first evidence that hFSCs secretome effectively reduce liver fibrosis through the TGF-\(\beta\)/Smad pathway. We believe that the hFSC secretome as an acellular regenerative therapy and approaches can provide great potential for the treatment of liver fibrosis.

**Materials And Methods**

**Cell culture**

hFSSCs and human umbilical cord mesenchymal stem cell (hUCMSCs) were provided and extracted by our previous study\cite{13}. HSCs were purchased from the Chinese Academy of Medical Sciences, China. In brief, hFSSCs, hUCMSCs and HSCs were cultured in DMEM (Gibco, Grand island, U.S.) supplemented with 500 U/ml penicillin and 500 \(\mu\)g/ml streptomycin (Invitrogen, Shanghai, China), and 10% FBS (Gibco, Grand island, U.S.) at 37°C, with saturated humidity and 5% CO\(_2\). hFSSCs and hUCMSCs at the P5 were used for this study, and hFSSCs and hUCMSCs) secretome was collected as reported in our previous study\cite{13}. Briefly, cells were cultured and reached 70~80% confluence, placed in serum-free medium (SFM; Invitrogen, Shanghai, China), and incubated in 5% CO\(_2\) in a humidified condition. After cultured 24h, the conditioned medium (CM) was collected and centrifuged to purify for 10 min at 4 °C, 4000g. Next, 10 ml conditioned medium was re-centrifuged with Amicon Ultra Centrifugal Filters (Millipore Corp, Billerica, MA, USA) at 4 °C, 4000g, 2 h. At last, 300~500 \(\mu\)l supernatant solution was collected as cell-free secretome each time. The protein content was measured using the BCSA kit (Thermo Scientific, Rockford, IL, USA) according to the manufacturer’s instruction.

**CCL\(_4\)-induced liver fibrosis in rats**

Liver fibrosis was induced in Sprague Dawley (SD) rats (8-week old, female, 200g). All protocols and procedures were approved by the Animal Experiment Ethic Committee of Changchun University of Traditional Chinese Medicine (Approval NO. XW201903167). Detailed procedures for CCL\(_4\)-induced have been described in our published studies\cite{6}. Briefly, rats were administered with an intraperitoneal injection of 30% CCL\(_4\), 3ml/kg body weight twice weekly in olive oil. After eight weeks, CCL\(_4\) treated rats were randomly assigned into three groups (n=10 rats, tail vein injection/weekly): PBS group (1ml); hUCMSC secretome group (250\(\mu\)g, 1ml); hFSSC secretome group (250\(\mu\)g, 1ml). After 4 weeks, liver tissue and serum were collected. Livers were divided into two parts of preservation in 10% formalin and freezing at -80 °C.

**Histopathological analysis**
Liver tissues were processed for paraffin embedding by slicing into 4μm sections. Liver sections were stained with hematoxylin & eosin (H&E) and Masson and Sirius red according to standard protocols. We selected the liver section fields randomly to analyze the liver fibrosis. The percentage of collagen stained area was calculated via Image-Pro Plus. Immunohistochemistry (IHC) was measured with the Kit (Maixin KIT-9710, Fuzhou, China) in accordance with the manufacturer's instructions. In brief, the liver sections were deparaffinized, rehydrated, and incubated in a 99 °C water bath for 15 minutes. Then, the slide was incubated with 3% H₂O₂ for 15 minutes, and blocked with 10% normal goat serum for 1 h at 37 °C. Following with the incubation of primary antibody against PCNA (ab15497, 1:500 dilution, Abcam, Cambridge, UK), α-SMA (ab5694, 1:500 dilution, Abcam, Cambridge, UK), and HNF-4α(ab219610, 1:500 dilution, Abcam, Cambridge, UK) overnight at 4 °C. Next, slides were incubated with biotinylated goat-anti-rabbit IgG antibody. Add diaminobenzidine solution for 15 minutes at 37 °C, then incubated with avidin peroxidase reagent, and hematoxylin for counterstaining. Lastly, slides were photographed using an optical microscope (Olympus, Tokyo Metropolitan, Japan). We used 10 random fields per section and 10 sections in total (n=10 rats) for quantification of IHC results. The IHC results were calculated via Image-Pro Plus.

**Biochemical analysis**

The serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein (TP), total bilirubin (TBIL), alkaline phosphatase (ALP), gamma glutamyl transpeptidase (γ-GT) were assessed using the Automated Biochemical Analyzer (AU-680, Beckman, California, U.S.) according to the procedure. Liver homogenate (10%, w/v) was prepared by homogenizing the right lobe of liver on ice in 150 mMTris-HCl buffered saline (pH 7.2) using a polytron homogenizer (PT3100D; Kinematical, Lucerne, Switzerland). The levels of Malondialdehyde (MDA) and Hydroxyproline (Hyp) in liver tissue were measured using kits (NanjingJianCheng Bio., Nanjing, China) according to the manufacturer's instructions.

**Quantitative real-time PCR (qRT-PCR)**

HSCs were co-cultured with either PBS, hUCMSCsecretome, or hFFSCsecretome(5ng/ml) for 48h before samples were collected for mRNAextraction.Total RNA was isolated from HSCs using Trizol reagent (Invitrogen, Shanghai, China) according to the manufacturer's protocol. Then, 1μg total RNA was reverse-transcribed to give cDNA, which was used as the template, and combined with standard SYBR premix Ex Taq (Invitrogen, Shanghai, China) on the Real-Time PCR Detection System (Roche, Basel, Switzerland), and experiments were conducted in triplicate. The levels of EMT related genes (E-cadherin, Snail1, Vimentin, FSP1 and α-SMA), TGF-β/Smad signaling pathway related genes (TGF-β1, Smad2, Smad3, Smad7 and Collagen I), and the internal standard GAPDH mRNA were measured by qRT-PCR. The primers are listed in Table S1, and GAPDH served as the internal control. All reactions were performed in triplicate and the data were analyzed using the 2^ΔΔCt method.

**Immunofluorescence (IF) staining**
When HSCs reached 60~70% confluence on 24-well plates, they were cultured with either PBS, hUCMSCsecretome, or hFFSCsecretome (5ng/ml) for 48h. Next, HSCs were incubated with 4% paraformaldehyde at room temperature for 10 minutes, and then incubated with 1% bovine serum albumin (BSA, Biosharp, Wuhan, China) for 30 minutes. Cells were incubated with a primary antibody against α-SMA (ab5694, 1:100 dilution, Abcam, Cambridge, UK) for 1h, followed by incubation with a secondary antibody (goat anti-rabbit IgG, ab15007, 1:500 dilution, Abcam, Cambridge, UK) for 30 minutes at room temperature. Rhodamine phalloidin (Thermal Scientific, Waltham, U.S.) was stained for cytoskeleton. The nuclei were labeled with DAPI (Thermal Scientific, Waltham, U.S.). Fluorescent images were captured using an EVOS Cell Imaging System (Thermo Scientific, Waltham, U.S.).

**Western blotting**

HSCs were co-cultured with either PBS, hUCMSCsecretome, or hFFSCsecretome (5ng/ml) for 48h before samples were collected for protein extraction. Protein samples were mixed with SDS sample buffer and heated to 95 °C for 10 minutes, followed by separation on SDS-polyacrylamide gels. Resolved proteins were electro-blotted onto nitrocellulose membrane and probed with antibodies against TGF-β1(ab92486), Smad2(ab40855), Smad3(ab40854), Smad7(ab216428), Collagen I (ab90395) and β-actin(ab5694), (1:1000 dilution, Abcam, Cambridge, UK) overnight at 4°C (1:1000 dilution, Abcam, Cambridge, UK). Nitrocellulose membranes were then incubated with a secondary antibody, HRP-conjugated goat anti-rabbit IgG (ab15007), at room temperature for 2h, and visualized by chemiluminescent detection according to the manufacturer’s instructions (Immobilon western chemiluminescent HRP substrate, Millipore, Massachusetts, U.S.).

**Statistical analysis**

Statistical analysis was performed using GraphPad Prism Version 6. One-way ANOVA with Dunnett’s multiple comparisons test was used to test for statistically significant differences. All quantitative data are expressed as mean ± SD for at least three independent experiments, and p < 0.05 was considered to be statistically significant.

**Results**

**hFSSCsecretome reduced CCl₄-induced liver fibrosis in rats.**

To explore the effect of hFSSCsecretome on liver fibrosis, we used CCl₄-induced a liver fibrosis model in rats (Fig. 1a). Compared to the PBS group, gross morphology changes obviously in hFSSCsecretome group, including less fibrous nodular and more ruddy on the surface, more uniform surface and soft texture (Fig. 1b). After 4 weeks treatment, histopathologic analysis using Masson and Sirius red staining indicated that the collagen area percentage in hFSSC group (9.2%) was significantly reduced, compared to the other two control groups (24.3% in PBS group and 14.9% in hUCMSCsecretome group, Fig. 1band 1c, p<0.05). Furthermore, we detected the MDA (a marker for oxidative stress and liver cell injury) and Hyp (a main component in collagen tissue) content in the liver tissue. We found that the level of MDA and Hyp in
hFSSC secretome group was significantly lower than the other two control groups (Fig. 1d and 1e, \( p < 0.01 \)). These findings suggest that hFSSC secretome effectively reduced CCl4-induced liver fibrosis in rats.

**hFSSCsecretome reduced liver fibrosis through suppressing the EMT**

To further verify the roles of hFSSC secretome in the pathogenesis of liver fibrosis, we performed immunofluorescence staining of TGF-\( \beta \) in HSCs. As TGF-\( \beta 1 \) is considered as a crucial mediator in tissue fibrosis, and HSCs are one of the major effector cells in liver fibrosis. We found that hFSSC secretome group reduced fluorescence intensity observably, compared to the other two control groups (Fig. 2a). In future study, we explore the effect of hFSSC secretome on EMT, and qRT-PCR analysis was used to examine the expression of EMT-related indicators (E-cadherin, Snail1, Vimentin, FSP1 and \( \alpha \)-SMA in HSCs). Interestingly, our results found that hFSSC secretome treatment increased the epithelial marker of E-cadherin expression, while decreased the transcription factors of Snail and mesenchymal markers (Vimentin, FSP1 and \( \alpha \)-SMA) expression, compared to the PBS group (Fig. 2b, \( p < 0.05 \)). Meanwhile, we also examined hFSSC secretome increased E-cadherin, and decreased FSP1 and \( \alpha \)-SMA expression compared to the hUCMSC secretome group (Fig. 2b, \( p < 0.05 \)). These results suggest that hFSSC secretome reduced liver fibrosis through suppressing the EMT.

**hFSSCsecretome improved liver functionality and promoted liver regeneration**

To explore the effect of hFSSC secretome on liver functionality, we performed the biochemical analyses. In comparison to the PBS group, hFSSC secretome group significantly reduced serum levels of ALT, AST, TBIL, \( \gamma \)-GT and ALP (Fig. 3a-3e, \( p < 0.05 \)). However, the serum level of TP in hFSSC secretome group was higher than that in PBS group (Fig. 3f, \( p < 0.05 \)). In addition, hFSSC secretome group significantly reduced the serum levels of TBIL and \( \gamma \)-GT compared to hUCMSC secretome group (Fig. 3c and 3d, \( p < 0.05 \)). These results suggest that hFSSC secretome effectively improved liver functionality.

Next, we performed IHC to assess the effects of the hFSSC secretome on the liver. \( \alpha \)-SMA is an important indicator of the occurrence and development of hepatic fibrosis. IHC results showed that the percentage of \( \alpha \)-SMA positive area in hFSSC secretome group (0.82%) was significantly decreased compared to the PBS group (5.51%, Fig. 4a and 4b, \( p < 0.001 \)). PCNA and HNF-4\( \alpha \) are two crucial indicators of hepatocyte proliferation. IHC results showed that the percentage of PCNA positive area in hFSSC secretome group (4.13%) was significantly increased compared to the PBS group (7.48%, Fig. 4a and 4c, \( p < 0.01 \)). Consist with the above results, the percentage of HNF-4\( \alpha \) positive area was significantly increased in hFSSC secretome group (12.1%), compared to the PBS group (4.5%, \( p < 0.01 \)) as well as hUC-MSCs group (8.2%, Fig. 4a and 4d, \( p < 0.05 \)). The histological results indicated that hFSSC secretome effectively delayed the progression of liver fibrosis, and promoted the liver regeneration.

**hFSSCsecretome regulate the TGF-\( \beta \)/Smad signal pathway**

To investigate the underlying mechanism of the effect of hFSSC secretome on liver fibrosis, we performed the Western blot and RT-qPCR to analysis the expression of TGF-\( \beta 1 \), Smad2, Smad3, Smad7 and Collagen...
I in HSCs, as it is one of the major effector cells in liver fibrosis. We found that TGF-β1, Smad2, Smad3, and Collagen I expression was significantly decreased in hFSSCsecretome group, compared that of PBS group (Fig. 5a and 5b, p<0.001). However, we detected the Smad7 was significantly increased in hFSSCsecretome group, compared that of the other two control groups (Fig.5a and 5b, p<0.01). Smad7 serves as a negative feedback regulator of TGF-β1/Smad pathway, thereby protects against TGF-β1-mediated fibrosis (Fig. 6). These results suggest that hFSSCsecretome effectively reduced liver fibrosis via regulating the TGF-β/Smad signal pathway (Fig5).

Discussion

In this study, our results demonstrated that hFSSCsecretome reduce liver fibrosis both in rats. Moreover, our research illustrated that hFSSCsecretome reduce liver fibrosis through suppressing the EMT and regulating the TGF-β/Smad signal pathway in HSCs.

Recent evidence indicates that the mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease[5, 14]. The use of MSC secretome has been shown to have anti-fibrotic effects[14]. Moreover, IV injection of hucMSC-EVs decreased liver fibrosis, reduced apoptosis and mitigated liver damage induced by CCl4 in mice[15, 16]. In our study, we found that hFSSCsecretome effectively reduced CCl4-induced liver fibrosis, and improved liver functionality in rats (Fig.1). Moreover, hFFSCssecretome treatment is more effective than of hUCMSCssecretome in resolving fibrosis, such as some indicators included collagen area, MDA, Hyp, TBIL, and γ-GT. The reasons that differences found between hUCMSCs and hFFSCssecretome may be reported that hFFSCssecretome contains more biological activity factors than hUCMSCssecretome[13]. Our studies indicated that hFSSCsecretome is an attractive emerging option for therapeutic applications as a therapeutic strategy for liver fibrosis.

Previous study that mesenchymal stem cell secretome inhibit HSC activation and promoted liver regeneration[17-19]. HSCs stimulate the production of a large amount of collagen fibers to form liver fibrosis. Moreover, positive expression of α-SMA can serve as a marker for HSCs activation[20]. Our results demonstrate that hFSSCsecretome decreased α-SMA expression. PCNAand HNF-4α is twocrucial indicator of hepatocyte proliferation[15]. Our study demonstrate that the percentage of PCNAand HNF-4α positive area was significantly increased after hFSSCsecretome treatment. These results confirmed that hFSSCsecretome promotes liver regeneration while reducing fibrosis. Despite our results confirming that hFSSCsecretome had significantly reduced liver fibrosis and caused no detectable immunological responses, their exact mechanisms of action need further exploration. Moreover, study has reported that type 2 EMT is associated with tissue regenerationand organ fibrosis. After CCl4 injury in liver, inflammatory cytokines, or chemical substances stimulate EMT to produce new collagen fibroblast pools to repair injury[5]. In present study, we demonstrated that hUCMSCssecretome reduced liver fibrosis through suppressing the EMT process.

The MSC secretome secreted some growth factors and cytokines, such as hepatocyte growth factor (HGF), transforming growth factor beta isoform 3 (TGF-β3), and tumor necrosis factor-alpha (TNF-α), and
IL-10 can modulate cell signaling and processes involved in fibrogenesis and can attenuate liver fibrosis[5, 21]. Recently, fetal mesenchymal stem cells functional secretome analysis illustrates that 737±80 protein identifications was obtained from the amniotic fluid-mesenchymal stem cells (AF-MSCs) secretome, interestingly, it reveals that Annexin-A1 as important paracrine factor in hepatic regeneration[22]. However, previous study demonstrated that hFSSC presented with the characteristics of both MSC and embryonic stem cell (ESC)[13]. These may be the partial reason that hFSSCsecretome can reduce liver fibrosis, and has better effects than hUCMSCsecretome in some indictors.

TGF-β1/Smad pathway is an important pathogenic mechanism in tissue fibrosis[23, 24]. Studies have shown that TGF-β1 is considered as a crucial mediator in tissue fibrosis and causes tissue scarring largely by activating its downstream small mother against decapentaplegic (Smad) signaling[25]. However, different TGF-β signalings play different roles in fibrogenesis[24]. TGF-β1 directly activates Smad signaling which triggers pro-fibrotic gene overexpression[26]. Increasing studies have demonstrated that dysregulation of TGF-β1/Smad pathway was an important pathogenic mechanism in tissue fibrosis[27]. Smad2 and Smad3 are the two major downstream regulator that promote TGF-β1 mediated tissue fibrosis, while Smad7 serves as a negative feedback regulator of TGF-β1/Smad pathway thereby protects against TGF-β1-mediated fibrosis[24]. Our findings proved that hFSSCsecretome effectively reduced TGF-β1, Smad2, Smad3, and Collagen I expression, moreover, increased Smad7 expression. It indicated that hFSSCsecretome effectively reduced liver fibrosis via regulating the TGF-β/Smad signal pathway (Fig. 6).

In conclusion, we successfully investigated the role of hFSSCsecretome on cutaneous liver fibrosis. Our results demonstrated that hFSSCsecretome can exert promoting effect of liver fibrosis via regulating the TGF-β/Smad signal pathway.

**Abbreviations**

hFSSC: Human fetal skin-derived stem cell; MSCs: mesenchymal stem cells; hUCMSCs: human umbilical cord mesenchymal stem cell; HSCs: Hepatic stellate cells; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; γ- GT: Gamma glutamyl transpeptidase; ALP: Alkaline phosphatase; TP: Total protein; Hyp: Hydroxyproline; MDA: Malonaldehyde; qRT-PCR: Quantitative real-time PCR; α-SMA: Alpha-smooth muscle actin; HGF: Hepatocyte growth factor; EMT: Epithelial to mesenchymal transition; TNF-α: Tumor necrosis factor-alpha; ESC: Embryonic stem cell; FSP1: fibroblast-specific protein 1

**Declarations**

**Ethics approval and consent to participate**

All the protocols and procedures were approved by the Animal Experiment Ethics Committee of the Changchun University of Traditional Chinese Medicine, China (Approval NO. XW201903167). The
informed written consent form was approved by the Clinical Research Ethics Committee and signed by the donor before sample collection.

**Consent for publication**

Not applicable.

**Availability of supporting data**

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

**Competing interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

This work was supported by the National Natural Science Foundation of China (No.8762069).

**Authors' Contributions**

X.Y. carried out the cell culture and animal studies, and helped to draft the manuscript. J.W. carried out animal studies and qRT-PCR. J.Z. carried out WB and performed the statistical analysis. X.R. conceived of the study and participated in its design and coordination and helped to draft the manuscript.

**Acknowledgments**

The authors thank Professor Chen, Changchun University of Traditional Chinese Medicine, for his assistance in animal experiment.

**References**

1. Sun M, Kisseleva T: *Reversibility of liver fibrosis*. *Clinics and research in hepatology and gastroenterology* 2015, **39 Suppl 1**:S60-63.

2. Arriazu E, Ruiz de Galarreta M, Cubero FJ, Varela-Rey M, Perez de Obanos MP, Leung TM, Lopategi A, Benedicto A, Abraham-Enachescu I, Nieto N: *Extracellular matrix and liver disease*. *Antioxid Redox Signal* 2014, **21**(7):1078-1097.

3. Elpek GO: *Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update*. *World J Gastroenterol* 2014, **20**(23):7260-7276.

4. Konala VB, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R: *The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration*. *Cytotherapy* 2016, **18**(1):13-24.
5. Driscoll J, Patel T: The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease. Journal of gastroenterology 2019, 54(9):763-773.

6. Rong X, Liu J, Yao X, Jiang T, Wang Y, Xie F: Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/beta-catenin pathway. Stem Cell Res Ther 2019, 10(1):98.

7. Moerkamp AT, Lodder K, van Herwaarden T, Dronkers E, Dingenouts CK, Tengstrom FC, van Brakel TJ, Goumans MJ, Smits AM: Human fetal and adult epicardial-derived cells: a novel model to study their activation. Stem Cell Res Ther 2016, 7(1):174.

8. Ishii T, Eto K: Fetal stem cell transplantation: Past, present, and future. World J Stem Cells 2014, 6(4):404-420.

9. Zhang ZY, Teoh SH, Hui JH, Fisk NM, Choolani M, Chan JK: The potential of human fetal mesenchymal stem cells for off-the-shelf bone tissue engineering application. Biomaterials 2012, 33(9):2656-2672.

10. Xu J, Wang B, Sun Y, Wu T, Liu Y, Zhang J, Lee WY, Pan X, Chai Y, Li G: Human fetal mesenchymal stem cell secretome enhances bone consolidation in distraction osteogenesis. Stem Cell Res Ther 2016, 7(1):134.

11. Chan J, O'Donoghue K, de la Fuente J, Roberts IA, Kumar S, Morgan JE, Fisk NM: Human fetal mesenchymal stem cells as vehicles for gene delivery. Stem cells (Dayton, Ohio) 2005, 23(1):93-102.

12. Wang X, Jiao Y, Pan Y, Zhang L, Gong H, Qi Y, Wang M, Gong H, Shao M, Wang X et al: Fetal Dermal Mesenchymal Stem Cell-Derived Exosomes Accelerate Cutaneous Wound Healing by Activating Notch Signaling. Stem Cells Int 2019, 2019:2402916.

13. Rong X, Li J, Yang Y, Shi L, Jiang T: Human fetal skin-derived stem cell secretome enhances radiation-induced skin injury therapeutic effects by promoting angiogenesis. Stem Cell Res Ther 2019, 10(1):383.

14. Jang YJ, An SY, Kim JH: Identification of MFGE8 in mesenchymal stem cell secretome as an antifibrotic factor in liver fibrosis. BMB reports 2017, 50(2):58-59.

15. Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, Wang M, Zhou Y, Zhu W, Li W et al: Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem cells and development 2013, 22(6):845-854.

16. Lou G, Chen Z, Zheng M, Liu Y: Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med 2017, 49(6):e346.

17. Li Q, Zhou X, Shi Y, Li J, Zheng L, Cui L, Zhang J, Wang L, Han Z, Han Y et al: In vivo tracking and comparison of the therapeutic effects of MSCs and HSCs for liver injury. PLoS One 2013, 8(4):e62363.

18. Berardis S, Dwisthi Sattwika P, Najimi M, Sokal EM: Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects. World J Gastroenterol 2015, 21(3):742-758.

19. Eom YW, Shim KY, Baik SK: Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med 2015, 30(5):580-589.
20. Bataller R, Brenner DA: Liver fibrosis. Journal of Clinical Investigation 2005, 115(2):209-218.
21. Alfaifi M, Eom YW, Newsome PN, Baik SK: Mesenchymal stromal cell therapy for liver diseases. J Hepatol 2018, 68(6):1272-1285.
22. Zagoura D, Trohatou O, Makridakis M, Kollia A, Kokla N, Mokou M, Psaraki A, Eliopoulos AG, Vlahou A, Roubelakis MG: Functional secretome analysis reveals Annexin-A1 as important paracrine factor derived from fetal mesenchymal stem cells in hepatic regeneration. EBioMedicine 2019, 45:542-552.
23. Hu HH, Chen DQ, Wang YN, Feng YL, Cao G, Vaziri ND, Zhao YY: New insights into TGF-beta/Smad signaling in tissue fibrosis. Chemico-biological interactions 2018, 292:76-83.
24. Walton KL, Johnson KE, Harrison CA: Targeting TGF-beta Mediated SMAD Signaling for the Prevention of Fibrosis. Frontiers in pharmacology 2017, 8:461.
25. Mokoena D, Dhillip Kumar SS, Houreld NN, Abrahamse H: Role of photobiomodulation on the activation of the Smad pathway via TGF-beta in wound healing. Journal of photochemistry and photobiology B, Biology 2018, 189:138-144.
26. Grotendorst GR: Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine & growth factor reviews 1997, 8(3):171-179.
27. Lindert S, Wickert L, Sawitza I, Wiercinska E, Gressner AM, Dooley S, Breitkopf K: Transdifferentiation-dependent expression of alpha-SMA in hepatic stellate cells does not involve TGF-beta pathways leading to coinduction of collagen type I and thrombospondin-2. Matrix Biol 2005, 24(3):198-207.

Figures
Figure 1

hFSSC secretome reduced liver fibrosis in rats. a. Experimental design. b. The representative images of gross morphology, Masson and Sirius red staining analysis of liver. Bar = 1 mm), n = 10 rats. c. Quantitative analysis of the collagen area percentage at 4 weeks. d. Quantitative analysis of hepatic MDA and Hyp content. *p<0.05, **p<0.01, ***p<0.001. n = 10; mean ± SD.
Figure 2

hFSSC secretome reduced liver fibrosis through suppressing the EMT process. a. Representative images of immunofluorescence staining performed for TGF-β in HSCs. Bar = 200μm. b. Relative mRNA expression levels of EMT related gene, included of E-cadherin, Snail1, Vimentin, FSP1 and α-SMA in HSCs. Note that EMT: epithelial–mesenchymal transition; FSP1: fibroblast-specific protein 1; α-SMA: alpha smooth muscle actin. *p<0.05, **p<0.01, ***p<0.0001. n = 10, mean ± SD.
Figure 3

hFSSC secretome improves liver function in serum biochemical parameters. a. ALT: Alanine aminotransferase. b. AST: Aspartate aminotransferase. c. TBIL: Total bilirubin. d. γ-GT: Gamma glutamyl transpeptidase. e. ALP: Alkaline phosphatase. f. TP: Total protein. *p<0.05, **p<0.01, ***p<0.001. n = 10, mean ± SD.
Figure 4

Histological analysis of hFSSC secretome reduced liver fibrosis and promoted liver regeneration. a. Photomicrographs of liver tissue sections showing IHC staining for α-SMA, PCNA, and HNF-4α. Brown cells represent the positive expression, bar = 1 mm. b-d. The quantification of α-SMA, PCNA, and HNF-4α positive cells area. *p<0.05, **p<0.01, ***p<0.001. n = 10, mean ± SD.
Figure 5

hFSSC secretome inhibited the TGF-β/Smad signaling pathway in HSCs. a. Representative western blotting analysis for the expression of TGF-β1, Smad2, Smad3, Smad7, and Collagen I in HSCs. b. Relative mRNA expression levels of TGF-β1, Smad2, Smad3, Smad7, and Collagen I in HSCs. **p<0.001, *p<0.001. n =3, mean ± SD.
hFSSC secretome reduced liver fibrosis by regulating the TGF-β/Smad signaling pathway. hFSSC secretome inhibited TGF-β1 expression, and activated Smad7 expression which are activated by the binding of the TGF-β super family to the cell surface receptors. TGF-β1-mediated tissue fibrosis via Smad2/Smad3 which are the two major downstream regulators, while Smad7 serves as a negative feedback regulator of TGF-β1/Smad pathway, thereby protects against TGF-β1-mediated fibrosis. Furthermore, hFSSC secretome decreased the collagen I expression, thereby reduce liver fibrosis.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryMaterial.docx